Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Savient Pharmaceuticals, a specialty biopharmaceutical company, has appointed John Johnson as the new CEO of the company, effective 31 January 2011.
Subscribe to our email newsletter
Prior to joining Savient Pharma, Johnson worked as the senior vice president of Eli Lilly and the president of Lilly Oncology Business Unit.
Before Eli Lilly, he has served as the CEO of a developer of targeted biologic cancer treatments, ImClone Systems.
Johnson said he look forward to working with the dedicated and talented Savient employees to bring relief to those adult patients suffering from chronic gout refractory to conventional therapy.
"My focus will be on successfully launching Krystexxa globally in order to build value for all our stakeholders," Johnson said.